Author of

• 14490

  +

  P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14577

    +

    P2.04-087 - Detection of Mutations from Peripheral Blood in Patients with Non-Small Cell Lung Cancer with Fast Turn-Around (ID 3083)

    09:30 - 09:30  |  Author(s): A. Parr
    • Abstract

    Background:
    In non-small cell lung cancer (NSCLC) several genetic changes that have clinical consequences for targeted treatment approaches have been identified. As for EGFR Mutations there are already options for more than one line of treatment. For those patients with secondary changes like the T790M-mediated resistance to EGFR inhibitors irreversible tyrosine kinase inhibitors (TKI) seem to be a promising alternative. These options may however be limited to missing proof of such changes as with progressing tumor burden patients may be susceptible to higher mortality with necessary invasive procedures. The so called “Liquid Biopsy” – using peripheral blood to obtain timely information on genetic information in solid malignancies – seems to be the urgently needed solution to this problem. Methods are needed that hold the promise of fast-turn around and broad availability.
    
    Methods:
    Serum was tested from 130 patients with adenocarcinoma or squamous cell cancer of the lung. All patients received at least one line of systemic therapy. Frequencies of EGFR ex19dels, EGFR L848R and EGFR T790M were tested as well as KRAS G12C, D and V. The detected frequencies were correlated with expected frequencies obtained from published data (mycancergenome.com). Furthermore the results from serum were correlated to results obtained from the available tumor tissue. Additional samples of fresh blood were tested.
    
    Results:
    Correlation of mutation detection results from serum correlated significantly with measurement of the available tumor specimen. Furthermore expected frequencies were in line with published occurrence of genetic changes. There was however a potential bias as T790M mutations were higher than expected which may be due to cancer center specific patient selection. These results were in line with the fresh blood samples tested. Turn-Around of fresh samples was three (3) days.
    
    Conclusion:
    Mutation detection is feasible from peripheral blood with fast turn-around and high sensitivity and specificity. In addition samples can be used either fresh or as stored serum probes. This will allow faster treatment decisions and higher patient satisfaction due to shorter intervals until start of therapy. The Liquid Biopsy is a clear and medically needed alternative to analyzing tissue samples. Especially in cases of secondary changes to tumors during systemic therapy this method will be crucial.